Last updated on September 2018

A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged 6 Months or Older to <6 Years With Severe Atopic Dermatitis

Brief description of study

This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in patients 6 months to less than 6 years of age with severe atopic dermatitis (AD).

Clinical Study Identifier: TX212274

Find a site near you

Start Over

University of South Florida-Morsani College of Medicine

13801 Bruce B Downs Blvd. Suite 505 Tampa, FL USA
  Connect »